PREMPHASE 14 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Premphase 14, and what generic alternatives are available?
Premphase 14 is a drug marketed by Wyeth Pharms and is included in one NDA.
The generic ingredient in PREMPHASE 14 is estrogens, conjugated; medroxyprogesterone acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the estrogens, conjugated; medroxyprogesterone acetate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PREMPHASE 14?
- What are the global sales for PREMPHASE 14?
- What is Average Wholesale Price for PREMPHASE 14?
Summary for PREMPHASE 14
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | PREMPHASE 14 at DailyMed |
US Patents and Regulatory Information for PREMPHASE 14
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Pharms | PREMPHASE 14/14 | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-002 | Nov 17, 1995 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
